File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3748/wjg.v25.i11.1398
- Scopus: eid_2-s2.0-85063683447
- PMID: 30918432
- WOS: WOS:000461757300009
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients
Title | Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients |
---|---|
Authors | |
Keywords | Biomarker Hepatitis B Hepatocellular carcinoma Liver fibrosis Mac-2 binding protein glycosylation isomer |
Issue Date | 2019 |
Publisher | Baishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/1007-9327/index.htm |
Citation | World Journal of Gastroenterology, 2019, v. 25 n. 11, p. 1398-1408 How to Cite? |
Abstract | BACKGROUND:
Liver cirrhosis is a major risk factor for hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB). Serum Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel serological marker for fibrosis. The role of M2BPGi in prediction of HCC is unknown.
AIM:
To examine the role of serum M2BPGi in predicting HCC development in hepatitis B e antigen (HBeAg)-negative patients.
METHODS:
Treatment-naive CHB patients with documented spontaneous HBeAg seroconversion were recruited. Serum M2BPGi was measured at baseline (within 3 years from HBeAg seroconversion), at 5 years and 10 years after HBeAg seroconversion and expressed as cut-off index (COI). Multivariate cox regression was performed to identify predictors for HCC development. ROC analysis was used to determine the cut-off value of M2BPGi.
RESULTS:
Among 207 patients (57% male, median age at HBeAg seroconversion 40 years old) with median follow-up of 13.1 (11.8-15.5) years, the cumulative incidence of HCC at 15 years was 7%. Median M2BPGi levels were significantly higher in patients with HCC compared to those without HCC (baseline: 1.39 COI vs 0.38 COI, P < 0.001; 5-year: 1.45 COI vs 0.47 COI, P < 0.001; 10-year: 1.20 COI vs 0.55 COI, P = 0.001). Multivariate analysis revealed age at HBeAg seroconversion [odds ratio (OR) = 1.196, 95% confidence interval (CI): 1.034-1.382, P = 0.016] and baseline M2BPGi (OR = 4.666, 95%CI: 1.296-16.802, P = 0.018) were significant factors predictive of HCC. Using a cut-off value of 0.68 COI, baseline M2BPGi yielded AUROC of 0.883 with 91.7% sensitivity and 80.8% specificity.
CONCLUSION:
High serum M2BPGi within 3 years after HBeAg seroconversion was a strong predictor for subsequent HCC development in treatment-naive HBeAg-negative CHB patients. |
Persistent Identifier | http://hdl.handle.net/10722/269439 |
ISSN | 2023 Impact Factor: 4.3 2023 SCImago Journal Rankings: 1.063 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mak, LY | - |
dc.contributor.author | To, WP | - |
dc.contributor.author | Wong, DKH | - |
dc.contributor.author | Fung, JYY | - |
dc.contributor.author | Liu, F | - |
dc.contributor.author | Seto, WKW | - |
dc.contributor.author | Lai, CL | - |
dc.contributor.author | Yuen, RMF | - |
dc.date.accessioned | 2019-04-24T08:07:44Z | - |
dc.date.available | 2019-04-24T08:07:44Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | World Journal of Gastroenterology, 2019, v. 25 n. 11, p. 1398-1408 | - |
dc.identifier.issn | 1007-9327 | - |
dc.identifier.uri | http://hdl.handle.net/10722/269439 | - |
dc.description.abstract | BACKGROUND: Liver cirrhosis is a major risk factor for hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB). Serum Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel serological marker for fibrosis. The role of M2BPGi in prediction of HCC is unknown. AIM: To examine the role of serum M2BPGi in predicting HCC development in hepatitis B e antigen (HBeAg)-negative patients. METHODS: Treatment-naive CHB patients with documented spontaneous HBeAg seroconversion were recruited. Serum M2BPGi was measured at baseline (within 3 years from HBeAg seroconversion), at 5 years and 10 years after HBeAg seroconversion and expressed as cut-off index (COI). Multivariate cox regression was performed to identify predictors for HCC development. ROC analysis was used to determine the cut-off value of M2BPGi. RESULTS: Among 207 patients (57% male, median age at HBeAg seroconversion 40 years old) with median follow-up of 13.1 (11.8-15.5) years, the cumulative incidence of HCC at 15 years was 7%. Median M2BPGi levels were significantly higher in patients with HCC compared to those without HCC (baseline: 1.39 COI vs 0.38 COI, P < 0.001; 5-year: 1.45 COI vs 0.47 COI, P < 0.001; 10-year: 1.20 COI vs 0.55 COI, P = 0.001). Multivariate analysis revealed age at HBeAg seroconversion [odds ratio (OR) = 1.196, 95% confidence interval (CI): 1.034-1.382, P = 0.016] and baseline M2BPGi (OR = 4.666, 95%CI: 1.296-16.802, P = 0.018) were significant factors predictive of HCC. Using a cut-off value of 0.68 COI, baseline M2BPGi yielded AUROC of 0.883 with 91.7% sensitivity and 80.8% specificity. CONCLUSION: High serum M2BPGi within 3 years after HBeAg seroconversion was a strong predictor for subsequent HCC development in treatment-naive HBeAg-negative CHB patients. | - |
dc.language | eng | - |
dc.publisher | Baishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/1007-9327/index.htm | - |
dc.relation.ispartof | World Journal of Gastroenterology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Biomarker | - |
dc.subject | Hepatitis B | - |
dc.subject | Hepatocellular carcinoma | - |
dc.subject | Liver fibrosis | - |
dc.subject | Mac-2 binding protein glycosylation isomer | - |
dc.title | Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients | - |
dc.type | Article | - |
dc.identifier.email | Wong, DKH: danywong@hku.hk | - |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.email | Lai, CL: hrmelcl@hkucc.hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.authority | Wong, DKH=rp00492 | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3748/wjg.v25.i11.1398 | - |
dc.identifier.pmid | 30918432 | - |
dc.identifier.pmcid | PMC6429346 | - |
dc.identifier.scopus | eid_2-s2.0-85063683447 | - |
dc.identifier.hkuros | 297460 | - |
dc.identifier.volume | 25 | - |
dc.identifier.issue | 11 | - |
dc.identifier.spage | 1398 | - |
dc.identifier.epage | 1408 | - |
dc.identifier.isi | WOS:000461757300009 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1007-9327 | - |